BioSpace News Archive

Castle Connolly Private Health Partners, LLC (“CCPHP”), a leading membership-based (or “concierge”) practice conversion and support company, is pleased to announce a collaboration with Dr. Marc D. Grobman to establish a concierge medicine program at his practice.

The $10M Series A Preferred Unit financing was raised through a syndicate of high net-worth individuals, and the $8M Common Unit financing was raised through a separate group of investors.

Mr. Goswami will be responsible for driving planning, strategic partnerships and acquisitions, and will report to President and Chief Executive Officer, Francis deSouza.

Over the past few years we’ve witnessed new medical breakthroughs that are altering how diseases are treated in ways that seemed unimaginable just a decade ago.

Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, will present positive topline data from the landmark PROspective study for SymPtomatic relief of Essential tremor with Cala Therapy (PROSPECT) in a late-breaking poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders on September 25, 2019, in Nice, France.

Sagentia, the global product development and technology consultancy and a Science Group company, announces the launch of MediTheatre, its Virtual Reality ‘showroom’. Delegates at The MedTech Conference in Boston on September 23rd-25th, will be the first to interact with Sagentia-developed medical technology products through this new custom developed VR facility.

Phoenix Molecular Designs (PhoenixMD), a clinical stage biotechnology company developing precise cancer therapeutics targeting essential kinases, received clearance from the Food and Drug Administration (FDA) for PhoenixMD’s Investigational New Drug (IND) application for its proprietary PMD-026.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the 2019 Cell & Gene Meeting on the Mesa on October 3rd, 2019 at 5:00pm Pacific Time at the Park Hyatt Aviara Resort in the BlueRock Therapeutics Ballroom in Carlsbad, CA.

Menarini Silicon Biosystems, the pioneer of liquid biopsy and rare cell technologies, will host a symposium on the importance of liquid biopsy and circulating tumor cells (CTCs) in advancing precision medicine for patients with metastatic breast and prostate cancer.

FEops, a leader in personalized predictive planning for structural heart interventions, today announced its selection into Dassault Systèmes’ 3DEXPERIENCE Lab, an initiative to nurture and empower disruptive projects transforming society with a positive impact by leveraging collective intelligence.